Archive for the ‘Urology News’ Category

FDA finding on Xiaflex expected in September

Monday, August 26th, 2013

xiaflex peyronies disease

Will the FDA approve the Auxilium drug Xiaflex for Peyronie’s Disease?  News is expected during the first week of September.  Xiaflex consists of an enzyme which breaks down the plaque that causes curvature of the penis.  Trial studies indicate that the drug can reduce the degree of penile curvature in Peyronie’s disease and other symptoms for men with the disease, and results have been consistent in multiple phases. Urosciences will watch the Web for the latest news on Xiaflex for Peyronie’s Disease, and keep our viewers posted.  The drug is already in use for a crippling hand condition known as Dupuytren’s contracture.

This post was written by  UroSciences, developers of the PDAD Peyronie’s Disease Assessment Device for urologists and patients.

Join Urosciences on FaceBook and Twitter.




False positives on thousands of prostate cancer tests

Monday, August 26th, 2013

prostate cancer news

ABC News  is reporting that thousands of men in Pennsylvania, and possibly the world over,  may have received erroneous PSA test results showing higher than actual levels–and possibly leading to unnecessary biopsies.  PSA, or prostate specific antigen levels, are a benchmark physicians use to gauge the likelihood of prostate cancer in their patients.  According to the report,  the makers of the test issued a global recall in June, citing a 20-23% “positive bias”.  The specific product recalled is the Immulite PSA test.

Read more posts on prostate cancer news:

Sex After Radical Prostatectomy

Preventing Climacturia (Urine leakage during sex)

Exosomes and Prostate Cancer Diagnosis





Men with ED, diabetes, often unaware of Peyronie’s Disease

Wednesday, August 7th, 2013

The P.D.A.D., Peyronie’s Disease Assesment Device, by UroSciences

If you have erectile dysfunction, you may want to consult with your urologist on the possible presence of Peyronie’s Disease–especially if you also have diabetes. Recent studies suggest that men with erectile dysfunction may not be aware that they also have Peyronie’s Disease, and that it could be contributing to their ED symptoms. And, in men with both ED and Peyronie’s disease, who were previously unaware of their Peyronie’s, diabetes was also present in 40% of cases.  The study, conducted in Istanbul, Turkey, suggests that Peyronie’s disease should always be suspected in men with both ED and diabetes.

More UroSciences posts on Peyronie’s Disease news:

Overcome Embarrassment and Get Treatment for Peyronie’s Disease

The PDAD Device for Peyronie’s

Collagenase Injections for Peyronie’s Disease

3 Resources for Peyronie’s Disease




Xofigo prostate cancer drug reported to reduce pain

Wednesday, August 7th, 2013


Xofigo, a newly approved treatment for advanced prostate cancer that has spread to the bones, is said to reduce patient pain levels.  The drug, which mimics calcium by binding to bone tissue at tumor sites, has been shown to extend patient survival rates by three months. The binding action of  Xofigo allows physicians to target the precise location of bone tumors caused by prostate cancer, and minimizes bone damage caused by tumors.  It is reported that Xofigo may allow patients to delay chemotherapy and the use of morphine for pain management.  A Xofigo treatment can be administered in a few as 15 minutes.

This prostate cancer news is brought to you by UroSciences– makers of the UroStop variable tension penile loop for sexual incontinence and the PDAD Peyronie’s disease assessment device.



Experts continue to weigh in on prostate cancer and fish oil study

Friday, July 19th, 2013


For more than a week, we’ve been watching the fallout from the study that supposedly linked fish oil to prostate cancer, which took the media and the medical community by storm.  Over the last several days, experts have been weighing in on this controversial topic. It turns out that, while the this single study may have shown higher Omega-3 levels among those with prostate tumors, there’s no evidence to suggest that the fish oil actually caused the prostate tumors.  Here’s a great article we found that provides a very clear explanation of the fish oil prostate cancer study, and why you probably shouldn’t change your supplement regimen based on its results.

For radical prostatectomy physicians and patients, we’d like you to view our UroStop™ variable tension penile loop for preventing climacturia, or urine leaking during sex.

Study suggests caution for androgen deprivation therapy for prostate cancer

Thursday, July 18th, 2013


A new study may prompt doctors to be more cautious about prescribing androgen deprivation therapy for prostate cancer, or at least prostate cancer that doesn’t warrant aggressive treatment.  The study, performed by researchers at McGill University in Montreal, suggests that the hormone therapy for prostate cancer may be linked to kidney problems.  While androgen deprivation was once used only for life threatening prostate cancer, it is increasingly being used to treat non-advanced prostate cancer, with experts warning to assure that the benefits of androgen deprivation therapy outweigh the risks.

For radical prostatectomy patients and physicians, please view the UroStop™ device for preventing climacturia, or urine leakage during sex.

Collagenase injections for Peyronie’s disease performing well in studies

Wednesday, July 17th, 2013


Renal and Urology News recently reported that collagenase injections are out-performing placebos in recent studies known as” Impress I” and “Impress II” for the treatment of Peyronie’s disease, and it seems that the injections are effective regardless of the severity of the disease.  The phase 3 studies, performed by the Baylor College of Medicine in Houston, resulted in up to 39-degrees of improvement in penile curvature.  In addition, the subjects’ receiving the Peyronie’s injections had markedly reduced bother scores.

Visit our page for more information on the Peyronie’s Disease Assessment Device (P.D.A.D.), exclusively developed by UroSciences for both urologists and patients.